These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 37655662)
21. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183 [TBL] [Abstract][Full Text] [Related]
22. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028 [TBL] [Abstract][Full Text] [Related]
23. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732 [TBL] [Abstract][Full Text] [Related]
24. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
25. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation. Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157 [TBL] [Abstract][Full Text] [Related]
26. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274 [TBL] [Abstract][Full Text] [Related]
27. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145 [TBL] [Abstract][Full Text] [Related]
28. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518 [TBL] [Abstract][Full Text] [Related]
29. N Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901 [TBL] [Abstract][Full Text] [Related]
30. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154 [TBL] [Abstract][Full Text] [Related]
31. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8 Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533 [TBL] [Abstract][Full Text] [Related]
33. Potential Predictive Value of Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262 [No Abstract] [Full Text] [Related]
34. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346 [TBL] [Abstract][Full Text] [Related]
35. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis. Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984 [TBL] [Abstract][Full Text] [Related]
36. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656 [TBL] [Abstract][Full Text] [Related]